Home / Themes / Cannabis '24: Int'l Medical Cannabis
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 14 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
International medical cannabis offers compelling growth driven by expanding regulated markets in Europe, Australia, and Israel, coupled with increasing patient
International medical cannabis offers compelling growth driven by expanding regulated markets in Europe, Australia, and Israel, coupled with increasing patient adoption and robust EU-GMP supply chains, despite ongoing regulatory complexities.
Expanding regulated medical cannabis markets, particularly in Europe (Germany, UK) and Australia, are driving significant market value and patient growth. Germany's market is estimated at €1.15 billion in 2026, with the broader European market projected to reach €2-4 billion by 2028. Australia's market is also expected to grow at a CAGR of 6.54% from 2026-2034.
The professionalization of the international medical cannabis supply chain, underpinned by stringent EU-GMP certification, is facilitating cross-border trade and ensuring high product quality and consistency. Canada continues to be a dominant exporter, particularly to Germany, which remains heavily import-dependent.
Evolving regulatory frameworks in key jurisdictions, such as Germany's 2024 Cannabis Act, have simplified prescriptions and expanded patient access. This is complemented by a growing trend towards diversified product formats, including oils, capsules, and vaporizers, which cater to a wider range of patient needs and improve therapeutic options.
The international medical cannabis market faces significant regulatory uncertainty and fragmentation, with no unified EU framework. Recent policy shifts, including Germany's removal of cannabis flowers from GKV reimbursement and proposed tightening of telemedicine in Australia and Germany, introduce volatility and can impact market access and patient demand. Israel also faces regulatory overhauls and proposed import tariffs on Canadian cannabis.
Rapid market expansion and increased import volumes, particularly in Europe, have led to chronic oversupply and significant price compression. This trend is evident in Germany, where pharmacy flower prices fell 46% to €4.52/g, eroding margins for operators and accelerating M&A activity as sub-scale players struggle.
Despite maturing supply chains, operators face increasing pressure on operational efficiency and resilience. Challenges include managing contamination risks, ensuring consistent product quality across complex international supply chains, and navigating potential trade barriers or anti-dumping duties, as seen with Canadian imports into Israel.
Investment discussions, company-specific news, sentiment on international operations, regulatory impacts.
In-depth financial analysis, industry trends, and expert commentary on cannabis companies, including international players.
Patient experiences, product efficacy discussions, and regional medical cannabis access issues, particularly in Europe and Australia.
Discussions among industry professionals on regulatory changes, market entry strategies, supply chain challenges, and M&A activity in the European medical cannabis sector.
Not in registry
Metric/field Germany Medical Cannabis Market Value (EUR)
Cadence annual
Why it matters Directly measures the size and growth of the largest medical cannabis market in Europe, a core focus of the theme. Indicates overall market health and expansion.
Signal to watch Increasing market value and growth rates suggest strong underlying demand and favorable regulatory conditions.
Confidence: high
Matchedgrand_view_research_market_size_forecasts · access=file · map_only
Metric/field Europe Pharmaceutical Market Size (USD)
Cadence irregular
Why it matters Medical cannabis operates within the broader pharmaceutical sector. Growth in the overall European pharmaceutical market indicates a supportive environment for medical product development and distribution.
Signal to watch Consistent growth in the broader pharmaceutical market suggests a healthy regulatory and commercial landscape for medical products.
Confidence: medium
Not in registryaccess=api
Metric/field CP00MI15EA20M086NEST (Harmonized Index of Consumer Prices: Total for Euro Area)
Cadence monthly
Why it matters Inflation rates in the Euro Area affect consumer purchasing power for self-pay medical cannabis prescriptions and influence operational costs for companies.
Signal to watch Stable or declining inflation could support consumer spending on medical treatments and reduce cost pressures for businesses.
Confidence: medium
Not in registryaccess=api
Metric/field CLVMNACSCAB1GQDE (Real Gross Domestic Product for Germany)
Cadence quarterly
Why it matters Germany is a primary market for international medical cannabis. Its economic health, as indicated by real GDP growth, impacts consumer disposable income and overall business investment in the region.
Signal to watch Positive and accelerating GDP growth indicates a robust economic environment, potentially boosting demand and investment.
Confidence: high
Not in registryaccess=api
Metric/field EARETAILV01IXOBSAM (Volume of retail trade index, Euro area)
Cadence monthly
Why it matters Retail sales volume provides an indication of overall consumer spending and confidence in the Euro Area, which can indirectly affect the private-pay segment of the medical cannabis market.
Signal to watch Increasing retail sales volume suggests stronger consumer confidence and spending capacity, which can benefit discretionary health-related purchases.
Confidence: low
Not in registry
Metric/field Search interest for 'medizinisches cannabis' (Germany)
Cadence weekly
Why it matters Directly reflects public interest and awareness of medical cannabis in Germany, a key market, often correlating with policy changes and market growth.
Signal to watch Sustained or increasing search interest indicates growing public acceptance and potential patient base.
Confidence: high
Not in registry
Metric/field Total volume of medical cannabis imports (tonnes)
Cadence quarterly
Why it matters Germany is a major importer of medical cannabis. This data directly indicates supply chain activity and market demand.
Signal to watch Increasing import volumes suggest rising demand and expansion of the medical cannabis market.
Confidence: high
Not in registry
Metric/field Number of private medical cannabis prescriptions (UK)
Cadence annual
Why it matters The UK is a significant private medical cannabis market. Tracking prescription numbers provides a direct measure of patient access and market penetration.
Signal to watch Rising prescription numbers indicate increasing patient adoption and physician comfort with prescribing.
Confidence: high
Not in registry
Metric/field Number of Australians using cannabis for medical purposes (prescribed)
Cadence biennial / ad-hoc
Why it matters Australia is a growing market for medical cannabis. This metric indicates the size of the patient population and the effectiveness of access pathways.
Signal to watch An increasing number of prescribed users suggests market maturation and improved patient access.
Confidence: medium
Not in registry
Metric/field Number of active medical cannabis patient licenses (Israel)
Cadence annual
Why it matters Israel has one of the highest per capita medical cannabis usage rates and is a key market for some theme members. License numbers directly reflect patient growth.
Signal to watch Growth in patient licenses indicates expanding market reach and potentially favorable regulatory changes.
Confidence: high
Not in registry
Metric/field Total European Medical Cannabis Market Value (EUR)
Cadence annual
Why it matters Provides comprehensive, in-depth analysis and forecasts for the entire European medical cannabis market, crucial for understanding regional trends and opportunities.
Signal to watch Upward revisions in market forecasts and strong reported growth indicate a robust and expanding market.
Confidence: high
Not in registry
Metric/field Medical cannabis sales volume and value by country (e.g., Germany, UK, Australia)
Cadence monthly/quarterly
Why it matters These firms specialize in granular cannabis market data, offering insights into sales performance, product categories, and consumer preferences in key international medical markets.
Signal to watch Consistent growth in sales volume and value, particularly in target product categories (e.g., oils, flower), indicates strong market traction.
Confidence: high
Not in registry
Metric/field Consumer adoption rates and perceptions of cannabis for health/wellness (by region)
Cadence annual
Why it matters Provides insights into consumer attitudes, motivations, and usage patterns for cannabis in health and wellness, which can inform product development and marketing strategies.
Signal to watch Increasing consumer openness and reported benefits from medical cannabis use suggest growing market potential.
Confidence: medium
Matchedsimilarweb_website_traffic_engagement · access=file · map_only
Metric/field Monthly unique visitors and engagement metrics for top medical cannabis clinic/pharmacy websites (Germany, UK, Australia)
Cadence irregular
Why it matters Digital engagement with medical cannabis platforms is a leading indicator of patient interest, access, and market activity, especially with the rise of telemedicine.
Signal to watch Rising website traffic and engagement suggest increasing patient acquisition and digital channel effectiveness.
Confidence: medium
Matchediqvia_prescription_rx_data · access=file · map_only
Metric/field Medical cannabis prescription volumes and value (by product type/indication) in key European markets
Cadence irregular
Why it matters IQVIA is a global leader in healthcare data, providing highly detailed prescription and sales data for pharmaceutical products, including medical cannabis where available. This offers precise market tracking.
Signal to watch Growth in prescription volumes and value for specific medical cannabis products and indications indicates successful market penetration and therapeutic adoption.
Confidence: high
